peoplePerson
William G. Kaelin Jr.
William Kaelin is the Nobel laureate whose work on VHL and HIF-2α led directly to belzutifan.
Shared the 2019 Nobel Prize in Physiology or Medicine for discovering how cells sense oxygen; his VHL-HIF work defined the target for HIF-2α inhibitors now approved in kidney cancer.
Role
Sidney Farber Professor of Medicine; HHMI Investigator
Institution
Specialisms
VHL and HIF biologyKidney cancerOxygen sensing
Profiles
| Title | Journal | Year |
|---|---|---|
| HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing | Science | 2001 |
Pages like this
not linked directly; found by shared links- TermVon Hippel-Lindau disease
Shares Belzutifan, VHL / HIF oxygen sensing, HIF-2α, Renal cell carcinoma.
- TrialLITESPARK-022
Shares Belzutifan, HIF-2α, Renal cell carcinoma.
- TrialLITESPARK-005
Shares Belzutifan, HIF-2α, Renal cell carcinoma.
- InstitutionHarold C. Simmons Comprehensive Cancer Center, UT Southwestern
Shares Belzutifan, HIF-2α, Renal cell carcinoma.
- TrialLITESPARK-012
Shares Belzutifan, Renal cell carcinoma.
- PersonToni K. Choueiri
Shares Belzutifan, HIF-2α, Dana-Farber Brigham Cancer Center, Renal cell carcinoma.
- TechnologyCAIX PET (89Zr-girentuximab)
Shares VHL / HIF oxygen sensing, HIF-2α, Renal cell carcinoma.
- TermAngiogenesis
Shares Belzutifan, VHL / HIF oxygen sensing, HIF-2α.